OncoMatch/Clinical Trials/NCT06545331
Study of XB010 in Subjects With Solid Tumors
Is NCT06545331 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including XB010 and Pembrolizumab for locally advanced or metastatic solid tumors.
Treatment: XB010 · Pembrolizumab — This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Esophageal Carcinoma
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Breast Carcinoma
Triple-Negative Breast Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ and marrow function
Kidney function
adequate organ and marrow function
Liver function
adequate organ and marrow function
Adequate organ and marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Exelixis Clinical Site #4 · Irvine, California
- Exelixis Clinical Site #19 · Los Angeles, California
- Exelixis Clinical Site #10 · Washington D.C., District of Columbia
- Exelixis Clinical Site #18 · Orlando, Florida
- Exelixis Clinical Site #12 · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify